Spyre Therapeutics (SYRE) news

Spyre Therapeutics shares down 13.8% after co's experimental drug fails to meet threshold for monotherapy development in rheumatoid arthritis

Spyre Therapeutics (NASDAQ: SYRE) shares fell 13.8% following the release of topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2 SKYWAY basket trial, which evaluated SPY072 as a potential monotherapy. While both doses of SPY072 demonstrated statistically significant…

Spyre Therapeutics Inc: Jonestrading cuts target price to $121 from $140

Spyre Therapeutics Inc: Wedbush cuts target price to $123 from $130

Wedbush Securities has adjusted its price target for Spyre Therapeutics Inc (SYRE) to $123 from $130, while maintaining its "Outperform" rating, according to recent reports . This follows a series of updates regarding the company’s clinical trials and strategic shifts, including halt stand-alone…

Spyre Therapeutics Inc: Raymond James cuts target price to $114 from $121

Raymond James has revised its price target for Spyre Therapeutics Inc (NASDAQ:SYRE), lowering it to $114 from a previous $121, while maintaining its Strong Buy rating. The firm cited ongoing clinical programs and financial strength as key factors supporting its positive outlook. Spyre, a…

Spyre Therapeutics shares down 12.4% premarket after co's experimental drug fails to meet threshold for monotherapy development in rheumatoid arthritis

Spyre Therapeutics (NASDAQ:SYRE) shares fell 12.4% in premarket trading on August 26, 2026, following the company’s announcement that its experimental drug SPY072 did not meet the threshold for monotherapy development in rheumatoid arthritis (RA). The drug, an anti-TL1A monoclonal antibody, was…